Early Cardioprotective Effect of Sevoflurane

• Status: Completed
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

In vitro studies and in vivo animal experiments have shown that halogenated volatile anesthetics have a protective effect on the ischemic myocardium. In clinical settings however, anesthetic preconditioning may be of more interest. The aim of our study was to evaluate the cardioprotective effect of sevoflurane in patients undergoing off-pump coronary artery bypass surgery. We proposed that a cardioprotective effect of sevoflurane would save myocardial function, which we measured acceleration by esophageal Doppler and cardiac index with bolus thermodilution methods, both during brief ischemia and reperfusion.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Dubrava
• Treatments: Propofol; Sevoflurane

Criteria

Inclusion Criteria:

• the degree I or II of Cardiac Anesthesia Risk Evaluation score

• angiographically verified coronary artery disease

• left ventricular ejection fraction higher than 40%

Exclusion Criteria:

• atrioventricular conduction disturbances

• previously ventricular arrhythmias requiring antiarrhythmic treatment

• atrial fibrillation with rapid ventricular response

• myocardial infarction or stroke within 6 months

• diabetes mellitus

• end-stage of obstructive or restrictive pulmonary disease